gastric inhibitory polypeptide receptor; GIP receptor; GIP-R; glucose-dependent insulinotropic polypeptide receptor (GIPR)
Jump to navigation
Jump to search
Function
- receptor for gastric inhibitory polypeptide (GIP)
- activity is mediated by Gi proteins
- stimulates insulin release during hyperglycemia[2]
- stimulates glucagon release during hypoglycemia[2]
Structure
belongs to the G-protein coupled receptor 2 family
Compartment
Alternative splicing
named isoforms=2
Pharmacology
- tirzepatide, a dual GLP-1 receptor agonist & GIP receptor agonist, is an investigational agent for treatment of diabetest mellitus type-2[2]
More general terms
References
- ↑ UniProt http://www.uniprot.org/uniprot/P48546.html
- ↑ 2.0 2.1 2.2 2.3 Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial. Lancet 2021 Jun 25; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34186022 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01324-6/fulltext
Frias JP, Davies MJ, Rosenstock J et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021 Jun 25; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34170647 https://www.nejm.org/doi/10.1056/NEJMoa2107519